Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average recommendation of “Buy” from the eight analysts that are covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $21.00.

ZVRA has been the subject of a number of research reports. Roth Mkm lifted their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group dropped their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Maxim Group lifted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC acquired a new position in Zevra Therapeutics in the second quarter valued at $474,000. Vestal Point Capital LP purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at about $3,644,000. Jacobs Levy Equity Management Inc. grew its holdings in Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after buying an additional 17,557 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Zevra Therapeutics during the 3rd quarter valued at about $833,000. Finally, Propel Bio Management LLC purchased a new position in shares of Zevra Therapeutics during the 3rd quarter worth about $1,248,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Trading Down 1.8 %

Shares of ZVRA stock opened at $9.33 on Monday. The business’s fifty day moving average price is $8.35 and its 200 day moving average price is $6.82. The firm has a market capitalization of $498.00 million, a PE ratio of -4.74 and a beta of 1.93. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. During the same period last year, the company earned ($0.40) earnings per share. As a group, sell-side analysts forecast that Zevra Therapeutics will post -1.96 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.